[Recent progress in the study on antitumor drugs targeting hypoxia-inducible factor-1].
Hypoxia-inducible factor-1 (HIF-1), as a transcription factor, plays an important role in the adaptation to hypoxic microenvironment within tumors. It can induce a series of genes transcription that participate in angiogenesis, glucose metabolism, cell proliferation, and cell migration/invasion. Thus HIF-1 not only allows cancer cells to survive in hypoxic microenvironment, but also makes the tumor more aggressive. Moreover, HIF-1 also induces tumors to acquire resistance to chemo-/radio-therapy, and is related to poor prognosis. HIF-1 emerges gradually as a potential target to develop new antitumor drugs. This paper reviews recent progress in this field.
Wang
Jing-Jian
JJ
School of Medicine and Pharmacy, Ocean University of China, Qingdao 266003, China.
Li
Jing
J
Geng
Mei-Yu
MY
D000666:Amphotericin B / Q000494:pharmacology; D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D004448:Echinomycin / Q000494:pharmacology; D006801:Humans; D051793:Hypoxia-Inducible Factor 1 / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism*; D007191:Indazoles / Q000494:pharmacology; D020123:Sirolimus / Q000031:analogs & derivatives / Q000494:pharmacology; D019772:Topotecan / Q000494:pharmacology; D014158:Transcription, Genetic
D000970:Antineoplastic Agents; D051793:Hypoxia-Inducible Factor 1; D007191:Indazoles; C090937:3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole; D004448:Echinomycin; C401859:temsirolimus; D019772:Topotecan; D000666:Amphotericin B; D020123:Sirolimus